Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by Centre for Endocrinology and Reproductive Medicine, Italy
Information provided by (Responsible Party):
Fabio Scarpellini, Centre for Endocrinology and Reproductive Medicine, Italy Identifier:
First received: October 17, 2012
Last updated: February 3, 2015
Last verified: February 2015

In this study the effectiveness of degarelix, a long acting GnRH antagonist administered in a unique administration of 20 mg the first day of menstrual cycle, to prevent ovarian hyperstimulation syndrome (OHSS) in PCOS women at risk to develop OHSS.

Condition Intervention Phase
Drug: degarelix (long acting GnRH antagonist)
Drug: cetrorelix 0.25mg
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Use of Long Acting GnRH Antagonist to Prevent Ovarian HyperStimulation Syndrome (OHSS) in PCOS Women Undergoing COH for IVF

Resource links provided by NLM:

Further study details as provided by Centre for Endocrinology and Reproductive Medicine, Italy:

Primary Outcome Measures:
  • PREGNANCY RATE [ Time Frame: 6 MONTHS ] [ Designated as safety issue: No ]
    number of ongoing pregnancy obtained in the group

  • ovarian hyperstimulation syndrome rate [ Time Frame: 6 MONTHS ] [ Designated as safety issue: Yes ]
    incidence of ovarian hyperstimulation syndrome in the groups

Secondary Outcome Measures:
  • implantation rate [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    number of implanted embryos divided for the number of transferred embryos

Other Outcome Measures:
  • number of mature oocytes [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    number of mature oocytes obtained in each patient

Estimated Enrollment: 80
Study Start Date: November 2012
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: degarelix group
group of patients treated with long acting GnRH antagonist
Drug: degarelix (long acting GnRH antagonist)
20 mg of degarelix the first day of menstrual cycle before starting with gonadotrophins administration
Other Name: Firmagon
Active Comparator: Cetrorelix 0.25mg
patients treated with gonadotropin and Cetrorelix ina flexible GnRH antagonist protocol
Drug: cetrorelix 0.25mg
0.25mg of cetrorelix during treatment with gonadotrophins when estradiol levels were >300pg/ml
Other Name: cetrotide

Detailed Description:

Women with PCOS are at risk to develop OHSS when stimulated with gonadotrophins for IVF. For this reason in this study the degarelix was tested in order to minimize the risk of OHSS as well as to improve the pregnancy rate in these patients. The use of long acting GnRH antagonist promotes a deep suppression of LH and consequently the activity of theca cells, which secrete androgens (the precursors of estradiol), and consequently the levels of estradiol remains low. Comparing the long acting GnRH antagonist at the first day of cycle with a flexible GnRH antagonist protocol in a group of patients with PCOS will be useful in order to establish the best way to perform controlled hyperstimulation in IVF cycles and minimize the risk of OHSS.


Ages Eligible for Study:   20 Years to 38 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • women with PCOS
  • previous OHSS
  • Infertility

Exclusion Criteria:

  • more than 38 years old
  • Body mass index pore than 30
  • other systemic diseases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01709942

Cerm-Hungaria Recruiting
Rome, Italy, 00153
Contact: Marco Sbracia, MD    +393479037433   
Contact: Fabio Scarpellini, MD    +393278779064   
Principal Investigator: Marco Sbracia, MD         
Sub-Investigator: Fabio Scarpellini, MD         
Sponsors and Collaborators
Centre for Endocrinology and Reproductive Medicine, Italy
Study Chair: Marco Sbracia, MD Centre for Endocrinology and Reproductive Medicine, Italy
  More Information

Responsible Party: Fabio Scarpellini, Principal Investigator, Centre for Endocrinology and Reproductive Medicine, Italy Identifier: NCT01709942     History of Changes
Other Study ID Numbers: C05
Study First Received: October 17, 2012
Last Updated: February 3, 2015
Health Authority: Italy: Ministry of Health

Keywords provided by Centre for Endocrinology and Reproductive Medicine, Italy:
GnRH antagonist

Additional relevant MeSH terms:
Fertility Agents
Fertility Agents, Female
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses processed this record on February 27, 2015